NeuroScientific (ASX:NSB) reported an 80% response rate in fistulising Crohn’s and is launching a second Phase 2 trial to fast-track Australian approval.
26
14
NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?
NeuroScientific jumps on early Crohn’s stem cell results
NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients…
